Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 7/20 | 0.52 |
| ▸ | GCGR | P47871 | 6/20 | 0.51 |
| ▸ | GLP1R | P43220 | 2/20 | 0.51 |
| ▸ | GIPR | P48546 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751914 | 0.92 | GCGR (0.48) | GCGGCGRGLP1RGIPRHDAC8 | |
| SCHEMBL2651734 | 0.89 | GCG (0.46) | GCGGCGRGLP1RGIPR | |
| SCHEMBL4081867 | 0.89 | GCG (0.51) | GCGGCGRGLP1RGIPREPHX2 | |
| SCHEMBL4081870 | 0.89 | GCG (0.51) | GCGGCGRGLP1RGIPREPHX2 | |
| SCHEMBL6189133 | 0.89 | GCGR (0.54) | GCGGCGRGLP1RGIPRHDAC8 | |
| SCHEMBL6754077 | 0.88 | GCG (0.47) | GCGGCGRGLP1RGIPR | |
| SCHEMBL6750361 | 0.88 | GCG (0.43) | GCGGCGRGLP1RGIPRL3MBTL1 | |
| SCHEMBL2650367 | 0.88 | GCG (0.45) | GCGGCGRGLP1RGIPR | |
| SCHEMBL2650335 | 0.88 | EPHX2 (0.46) | GCGGCGRGLP1RGIPREPHX2 | |
| SCHEMBL2651267 | 0.88 | GCG (0.43) | GCGGCGRGLP1RGIPREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | MADSEN PETER (DK) | 2004-07-01 | — | — | US | claimed |
| US-6706744-B2 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2004-03-16 | — | — | US | claimed |
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-04-03 | — | — | US | claimed |
| WO-2002040444-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCG 6/4885GCGR 3/4885GLP1R 1/4885 |
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCG 6/4885GCGR 3/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.